Immunostaining of galectin-3 CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma

被引:30
|
作者
Maruta, J
Hashimoto, H
Yamashita, H
Yamashita, H
Noguchi, S
机构
[1] Noguchi Thyroid Clin & Hosp Fdn, Dept Pathol, Beppu, Oita 8740932, Japan
[2] Noguchi Thyroid Clin & Hosp Fdn, Dept Surg, Beppu, Oita 8740932, Japan
关键词
immunostaining; galectin-3; CD44v6; aspiration cytology; thyroid follicular tumor;
D O I
10.1002/dc.20156
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To evaluate the clinical applicability of galectin-3 and CD44 variant 6 (CD44v6) inummostaining in fine-needle aspiration cytology (FNAC) of thyroid follicular tumors, 79 cytological specimens (35 follicular carcinomas and 44 follicular adenomas) were studied. The positive rates of galectin-3 and CD44v6 were 89 and 74% in follicular carcinoma, respectively, and 25 and 30% in follicular adenoma, respectively. There were no significant correlations between the expression of galectin-3 or CD44v6 in follicular carcinoma and characteristics such as capsular invasion, vascular invasion, metastasis, or tumor size. Positive staining of either galectin-3 or CD44v6 resulted in a diagnostic sensitivity of 97% and a specificity of 52% for follicular carcinoma among follicular tumors. Immunostaining of galectin-3 or CD44v6 using cytological specimens can provide independent information on conventional morphological findings of cytology to distinguish follicular carcinoma from adenoma. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:392 / 396
页数:5
相关论文
共 50 条
  • [1] Galectin-3 and CD44V6 expression in thyroid lesions
    Kourea, Helen
    Liava, Anna
    Vagianos, Constantinos
    Scopa, Chrisoula
    VIRCHOWS ARCHIV, 2007, 451 (02) : 358 - 359
  • [2] Co-expression of galectin-3 and CD44v6 is helpful in the diagnosis of thyroid carcinoma with follicular growth pattern
    Hutzler, MJ
    Ali, I
    Witkiewicz, A
    Patwardhan, NA
    Safran, M
    Khan, A
    MODERN PATHOLOGY, 2001, 14 (01) : 77A - 77A
  • [3] Co-expression of Galectin-3 and CD44v6 is helpful in the diagnosis of thyroid carcinoma with follicular growth pattern
    Hutzler, MJ
    Ali, I
    Witkiewicz, A
    Patwardhan, NA
    Safran, M
    Khan, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 77A - 77A
  • [4] Absence of Galectin-3 Immunostaining in Fine-Needle Aspiration Cytology Specimens from Papillary Thyroid Carcinoma Is Associated with Favorable Pathological Indices
    Kim, Eun Sook
    Lim, Dong Jun
    Lee, Kyungji
    Jung, Chan Kwon
    Bae, Ja Seong
    Jung, So Lyung
    Baek, Ki Hyun
    Lee, Jong Min
    Moon, Sung Dae
    Kang, Moo Il
    Cha, Bong Yun
    Lee, Kwang Woo
    Son, Ho Young
    THYROID, 2012, 22 (12) : 1244 - 1250
  • [5] Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples
    J F Collet
    I Hurbain
    C Prengel
    O Utzmann
    F Scetbon
    J F Bernaudin
    A Fajac
    British Journal of Cancer, 2005, 93 : 1175 - 1181
  • [6] Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples
    Collet, JF
    Hurbain, I
    Prengel, C
    Utzmann, O
    Scetbon, F
    Bernaudin, JF
    Fajac, A
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1175 - 1181
  • [7] Galectin-3 immunodetection in follicular thyroid neoplasms : A prospective study on fine-needle aspiration samples
    Collet, Jean-Francois
    Hurbain, Ilse
    Prengel, Claudie
    Utzmann, Olivier
    Scetbon, Fabienne
    Bernaudin, Jean-Francois
    Fajac, Anne
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions
    Matesa, N.
    Samija, I.
    Kusic, Z.
    CYTOPATHOLOGY, 2007, 18 (02) : 112 - 116
  • [9] CD44v6和Galectin-3与甲状腺肿瘤
    王丽华
    国际内分泌代谢杂志, 2003, (S1) : 39 - 41
  • [10] Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules
    Gasbarri, A
    Martegani, MP
    Del Prete, F
    Lucante, T
    Natali, PG
    Bartolazzi, A
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3494 - 3502